All Ariad articles
-
BusinessTakeda tightens focus on core areas with multiple deals
Japanese firm is remodelling its R&D efforts through collaboration and licensing deals, and selling off non-core businesses
-
BusinessJob cuts at Amgen, Takeda and Vertex
Takeda reorganising following Ariad takeover, while Amgen and Vertex move staff to Cambridge and San Francisco hubs
-
BusinessTakeda to buy cancer specialist Ariad
Japan’s largest drug company agrees $5.2bn deal to expand oncology portfolio and boost pipeline
-
Business
More testing needed for ridaforolimus
Marketing approval for anti-cancer drug ridaforolimus has been held up in the US